Literature DB >> 22190182

Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach.

Paqui G Través1, Pedro de Atauri, Silvia Marín, María Pimentel-Santillana, Juan-Carlos Rodríguez-Prados, Igor Marín de Mas, Vitaly A Selivanov, Paloma Martín-Sanz, Lisardo Boscá, Marta Cascante.   

Abstract

The activation of immune cells in response to a pathogen involves a succession of signaling events leading to gene and protein expression, which requires metabolic changes to match the energy demands. The metabolic profile associated with the MAPK cascade (ERK1/2, p38, and JNK) in macrophages was studied, and the effect of its inhibition on the specific metabolic pattern of LPS stimulation was characterized. A [1,2-[(13)C](2)]glucose tracer-based metabolomic approach was used to examine the metabolic flux distribution in these cells after MEK/ERK inhibition. Bioinformatic tools were used to analyze changes in mass isotopomer distribution and changes in glucose and glutamine consumption and lactate production in basal and LPS-stimulated conditions in the presence and absence of the selective inhibitor of the MEK/ERK cascade, PD325901. Results showed that PD325901-mediated ERK1/2 inhibition significantly decreased glucose consumption and lactate production but did not affect glutamine consumption. These changes were accompanied by a decrease in the glycolytic flux, consistent with the observed decrease in fructose-2,6-bisphosphate concentration. The oxidative and nonoxidative pentose phosphate pathways and the ratio between them also decreased. However, tricarboxylic acid cycle flux did not change significantly. LPS activation led to the opposite responses, although all of these were suppressed by PD325901. However, LPS also induced a small decrease in pentose phosphate pathway fluxes and an increase in glutamine consumption that were not affected by PD325901. We concluded that inhibition of the MEK/ERK cascade interferes with central metabolism, and this cross-talk between signal transduction and metabolism also occurs in the presence of LPS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190182     DOI: 10.4049/jimmunol.1101781

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Cell Origin Dictates Programming of Resident versus Recruited Macrophages during Acute Lung Injury.

Authors:  Kara J Mould; Lea Barthel; Michael P Mohning; Stacey M Thomas; Alexandra L McCubbrey; Thomas Danhorn; Sonia M Leach; Tasha E Fingerlin; Brian P O'Connor; Julie A Reisz; Angelo D'Alessandro; Donna L Bratton; Claudia V Jakubzick; William J Janssen
Journal:  Am J Respir Cell Mol Biol       Date:  2017-09       Impact factor: 6.914

2.  Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.

Authors:  L-N Fu; Y-Q Wang; J Tan; J Xu; Q-Y Gao; Y-X Chen; J-Y Fang
Journal:  Oncogene       Date:  2017-09-25       Impact factor: 9.867

3.  Glycolytic inhibitor 2-deoxyglucose suppresses inflammatory response in innate immune cells and experimental staphylococcal endophthalmitis.

Authors:  Rebecca Francis; Pawan Kumar Singh; Sukhvinder Singh; Shailendra Giri; Ashok Kumar
Journal:  Exp Eye Res       Date:  2020-05-23       Impact factor: 3.467

4.  Activity-dependent neuronal Klotho enhances astrocytic aerobic glycolysis.

Authors:  Caio H Mazucanti; Elisa M Kawamoto; Mark P Mattson; Cristoforo Scavone; Simonetta Camandola
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-01       Impact factor: 6.200

5.  Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18F-FDG PET imaging of atherosclerosis.

Authors:  Sina Tavakoli; Debora Zamora; Sarah Ullevig; Reto Asmis
Journal:  J Nucl Med       Date:  2013-07-25       Impact factor: 10.057

6.  Metabolic Reprogramming of Host Cells by Virulent Francisella tularensis for Optimal Replication and Modulation of Inflammation.

Authors:  Elliott V Wyatt; Karina Diaz; Amanda J Griffin; Jed A Rasmussen; Deborah D Crane; Bradley D Jones; Catharine M Bosio
Journal:  J Immunol       Date:  2016-03-30       Impact factor: 5.422

7.  Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype.

Authors:  Min Liu; Fengling Luo; Chuanlin Ding; Sabrin Albeituni; Xiaoling Hu; Yunfeng Ma; Yihua Cai; Lacey McNally; Mary Ann Sanders; Dharamvir Jain; Goetz Kloecker; Michael Bousamra; Huang-ge Zhang; Richard M Higashi; Andrew N Lane; Teresa W-M Fan; Jun Yan
Journal:  J Immunol       Date:  2015-10-09       Impact factor: 5.422

8.  Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer.

Authors:  Min Liu; Zan Tong; Chuanlin Ding; Fengling Luo; Shouzhen Wu; Caijun Wu; Sabrin Albeituni; Liqing He; Xiaoling Hu; David Tieri; Eric C Rouchka; Michito Hamada; Satoru Takahashi; Andrew A Gibb; Goetz Kloecker; Huang-Ge Zhang; Michael Bousamra; Bradford G Hill; Xiang Zhang; Jun Yan
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

9.  HIF-1α and PFKFB3 Mediate a Tight Relationship Between Proinflammatory Activation and Anerobic Metabolism in Atherosclerotic Macrophages.

Authors:  Ahmed Tawakol; Parmanand Singh; Marina Mojena; María Pimentel-Santillana; Hamed Emami; Megan MacNabb; James H F Rudd; Jagat Narula; José A Enriquez; Paqui G Través; María Fernández-Velasco; Ramón Bartrons; Paloma Martín-Sanz; Zahi A Fayad; Alberto Tejedor; Lisardo Boscá
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-16       Impact factor: 8.311

10.  MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.

Authors:  Vivek Verma; Nazli Jafarzadeh; Shannon Boi; Subhadip Kundu; Zhinuo Jiang; Yiping Fan; Jose Lopez; Rahul Nandre; Peng Zeng; Fatmah Alolaqi; Shamim Ahmad; Pankaj Gaur; Simon T Barry; Viia E Valge-Archer; Paul D Smith; Jacques Banchereau; Mikayel Mkrtichyan; Benjamin Youngblood; Paulo C Rodriguez; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2020-11-23       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.